StockData
ImmuCell Corp logo

ImmuCell Corp (ICCC) stock

ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/303% above fair value
$11.33−0.09 (-0.79%)

Close on Nov 17, 2026Market cap $102.90MP/E 141.6Yield –

ImmuCell pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

ImmuCell's pe ratio was 127.4× on Nov 11, 2026, against 729.0× a year earlier. Over the last 5 years it ranged from 15.7× to 899.0×, with a median of 52.5×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026127.4×+103.7
2025Dec 31, 202523.7×−777.3
2022Oct 31, 2022801.0×+1.0
2021Dec 31, 2021800.0×+68.0
2018Jan 31, 2018732.0×−147.0
2017Dec 29, 2017879.0×+850.7
2016Dec 30, 201628.3×+5.5
2015Dec 31, 201522.8×−79.7
2014Apr 30, 2014102.5×+49.1
2013Dec 31, 201353.4×−46.6
2012Dec 31, 2012100.0×–

More ImmuCell figures

See a number that looks wrong?